Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.